Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Colorado Anschutz

Sites in Aurora, CO

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1010
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Colorado Anschutz, Aurora, CO
Additional filters apply within this campus.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this campus

These controls apply only within University of Colorado Anschutz, Aurora, CO. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 361–372 of 1,010 matching trials with a site at University of Colorado Anschutz, Aurora, CO.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma

NCT04339738
Site status not listed — check the official record
View directory record Official record
Conditions
Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma, Visceral Angiosarcoma
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Nivolumab, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
170
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 15, 2026, 8:07 PM EDT
Active, not recruiting Phase 2 Interventional

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

NCT03897881
Site status not listed — check the official record
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, mRNA-4157
Biological · Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
17
States / cities
Tucson, Arizona • San Francisco, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 13, 2026, 10:49 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

NCT03715933
Status at this site: Recruiting
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Ewing Sarcoma
Interventions
Bevacizumab, Fluorouracil, INBRX-109, Irinotecan, Leucovorin, Temozolomide, Trifluridine + Tipiracil, carboplatin, pemetrexed
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
12 Years to 85 Years
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
24
States / cities
Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 13, 2026, 10:38 PM EDT
Recruiting No phase listed Observational

An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)

NCT07264959
Status at this site: Recruiting
View directory record Official record
Conditions
Indolent Systemic Mastocytosis
Interventions
Not listed
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
7
States / cities
Aurora, Colorado • Normal, Illinois • Wheaton, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 14, 2026, 3:57 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

NCT06868290
Site status not listed — check the official record
View directory record Official record
Conditions
ANCA Associated Vasculitis (AAV)
Interventions
Active Comparator, Glucocorticoids, Rapcabtagene autoleucel
Other · Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
14
States / cities
Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 15, 2026, 12:56 AM EDT
Recruiting Phase 1 Interventional

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

NCT06430541
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
Psilocybin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 17, 2026, 12:35 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

NCT06047444
Site status not listed — check the official record
View directory record Official record
Conditions
Chronic Migraine
Interventions
Botulinum toxin type A, Placebo
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 13, 2026, 4:04 PM EDT
Recruiting Phase 1 Interventional

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

NCT05711615
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Myxofibrosarcoma, Unresectable Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 14, 2026, 11:29 AM EDT
Active, not recruiting Phase 2 Interventional

To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

NCT04597359
Site status not listed — check the official record
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Sinecatechins
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
21 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
345
States / cities
Fairbanks, Alaska • Phoenix, Arizona • Fayetteville, Arkansas + 224 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 16, 2026, 11:38 AM EDT
Not yet recruiting Not applicable Interventional

Digitally Enhanced Cognitive-Behavioral Therapy

NCT07569991
Site status not listed — check the official record
View directory record Official record
Conditions
Cognitive-behavioral Therapy, Depression in Adolescence, Health Behavior, Mobile Health Technology (mHealth), Obesity & Overweight
Interventions
Cognitive-behavioral therapy (CBT), Digital app
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 14, 2026, 9:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

NCT07491497
Status at this site: Recruiting
View directory record Official record
Conditions
ALK-Positive Lung Cancer, ALK-positive NSCLC, ALK-positive Non-small Cell Lung Cancer
Interventions
TRI-611
Drug
Lead sponsor
TRIANA Biomedicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 18, 2026, 9:31 AM EDT
Active, not recruiting Not applicable Interventional

BfedBwell INSPIRE Pilot

NCT07446595
Site status not listed — check the official record
View directory record Official record
Conditions
Cancer Survivorship, Overweight , Obesity
Interventions
BfedBwell - 1:1 Counseling, BfedBwell - Behavioral Skills, BfedBwell - Core Curriculum, BfedBwell - Group Support, BfedBwell - Technology, BfitBwell - Clinical Exercise Program
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 16, 2026, 1:20 AM EDT

About this University of Colorado Anschutz institution page

What this page lists
ClinicalTrials.gov records that list University of Colorado Anschutz in Aurora, CO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.